622 Shares in IQVIA Holdings Inc. (NYSE:IQV) Bought by LRI Investments LLC

LRI Investments LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 622 shares of the medical research company’s stock, valued at approximately $157,000.

Several other hedge funds have also recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in IQVIA during the first quarter worth $3,365,000. Stonebridge Capital Advisors LLC lifted its stake in IQVIA by 5.5% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 10,056 shares of the medical research company’s stock valued at $2,543,000 after acquiring an additional 520 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in IQVIA by 6.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock valued at $807,183,000 after acquiring an additional 193,304 shares in the last quarter. Capital Research Global Investors lifted its stake in IQVIA by 7.2% in the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after acquiring an additional 143,533 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in IQVIA by 106.4% in the 1st quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company’s stock valued at $328,000 after acquiring an additional 669 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 3.2 %

IQV stock traded up $7.38 during trading on Friday, hitting $239.67. 1,195,238 shares of the company traded hands, compared to its average volume of 1,420,984. The firm has a market capitalization of $43.69 billion, a PE ratio of 32.74, a P/E/G ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a 50-day moving average of $220.23 and a 200-day moving average of $229.46. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.88 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.22 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Truist Financial boosted their price target on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. Barclays boosted their price target on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a report on Wednesday. Finally, Morgan Stanley boosted their price target on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $263.56.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.